To assess the immune responses, both humoral and cellular, to the BNT162b2 and ChAdOx1 nCoV-19 vaccines over a 3-month period and compared the antibody and T cell responses induced by the vaccines with those generated by natural COVID-19 infection
Latest Information Update: 06 Dec 2021
At a glance
- Drugs AZD 1222 (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 06 Dec 2021 New trial record
- 25 Nov 2021 Results published in the Journal of Infectious Diseases